In the fiscal year under review, consolidated net sales increased year-on-year, operating income increased, ordinary income, and profit attributable to owners of the parent decreased.
●Consolidated net sales totaled 198,380 million yen, an increase of 13,574 million yen (7.3%) year-on-year. Sales in the pharmaceuticals business underperformed, while the functional chemicals and safety systems businesses outperformed the previous fiscal year.
●Consolidated operating income totaled 21,505 million yen, an increase of 454 million yen (2.2%) year-on-year, outperforming the previous fiscal year in the pharmaceuticals and safety systems businesses, while underperforming in the functional chemicals industry.
●Consolidated ordinary income totaled 23,025 million yen, a decrease of 128 million yen (0.6%) year-on-year.
●Profit attributable to owners of parent was 14,984 million yen, a decrease of 2,196 million yen (12.8%) year-on-year, owing to recognition of an impairment loss on property, plant, and equipment.

(yen)	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03
Net income per share	92.25	86.38	96.09	90.23	89.45	85.77	74.25	73.62	101.70	89.36
Net assets per share	918.35	1,030.16	1,075.56	1,120.74	1,203.23	1,247.75	1,225.71	1,332.06	1,459.06	-
Dividend per share	25	25	30	30	30	30	30	30	40	45
Dividend payout ratio	27.1%	28.9%	31.2%	33.2%	33.5%	35.0%	40.4%	40.7%	39.3%	50.4%